DBV Technologies

A proud moment for our team! We were featured on the Nasdaq Tower for #FoodAllergyAwarenessWeek; a meaningful reminder of the families we aim to serve. We’re dedicated to advancing pediatric #FoodAllergy care and supporting our community every step of the way. Discover more about our mission: https://bit.ly/3S6OALw #FAAW2026

Our team is coming together in teal to show support for the food allergy community. Behind our work are people with lived experiences and personal connections, as parents, physicians, advocates, and individuals who understand the impact food allergies can have on everyday life. We understand firsthand how food allergies may be unseen but should never be unnoticed. Sharing these perspectives is one way we continue to build awareness and strengthen our mission of advancing pediatric #FoodAllergy care. Learn more about our team and commitment: https://lnkd.in/eA4WWPw4 #FAAW2026

May is #FoodAllergyAwarenessMonth! For millions of families, food allergy is more than a diagnosis, it is a daily reality that requires constant awareness, preparation, and care. This month we’re highlighting the importance of education, advocacy, and continued progress in pediatric food allergy care. At DBV Technologies, we’re proud to work alongside organizations to create a future where children and families can navigate food allergies with confidence. Learn more from Allergy & Asthma Network, Asthma and Allergy Foundation of America, FARE, FAACT, Food Allergy & Anaphylaxis Connection Team, FAACT, Food Allergy & Anaphylaxis Connection Team, and Food Allergy Canada.

Today, we reported first quarter 2026 financial results. Read the full press release here: https://lnkd.in/gAjaWHBC

How can a potential #FoodAllergy treatment harness the powerful immune properties of the skin? Our VIASKIN® technology platform leverages epicutaneous immunotherapy (EPIT) to potentially desensitize patients to allergens like peanuts and milk by delivering microgram amounts of allergens through intact skin without entering the bloodstream. Watch the video to learn more: https://bit.ly/4fWxxFk

#PeanutAllergy often starts in early childhood and can persist into adulthood. For many families, this means years of daily caution, lifestyle changes, and emotional stress. We understand that food allergy management can feel overwhelming, and that every person’s journey is unique. That’s why we’re developing options that may allow families to take a more proactive approach to care. As part of our commitment to the food allergy community and offering solutions to families, regardless of where they are in their journey, we plan to expand our clinical research to include infants aged 6–12 months with peanut allergy in a first-of-its-kind Phase 2 study. In addition to clinical evidence across age groups, we believe epicutaneous immunotherapy (EPIT) has the potential to modify the trajectory of peanut allergy. Learn more about our technology and approach here: https://bit.ly/4fWxxFk

Passionate about innovation that makes an impact? Our team is focused on bringing VIASKIN® – our investigational treatment platform designed to alleviate the burden of #FoodAllergy care – to children and families. If you're looking to grow your career while delivering meaningful solutions that make a difference, explore our open roles across the U.S. and France: https://bit.ly/3Hk9uF0

In the U.S. alone, peanut allergy affects ~400,000 children between the ages of 4–7. A significant unmet need remains for more proactive approaches that not only reduce the frequency and severity of allergic reactions but also address existing barriers to care. VITESSE, our Phase 3 study in peanut-allergic children aged 4–7, evaluated the VIASKIN® Peanut Patch. Recent positive topline results were announced, followed by additional data presented last month. Subscribe to stay up to date on our latest data and presentations: https://bit.ly/495uSZD

We’re pleased to report our full year 2025 financial results, reflecting strong momentum and disciplined execution across clinical development, regulatory progress, and financial strategy. We remain on track to submit two separate BLAs in 4-7-year-olds and 1-3-year-olds, in the first half and second half of the year respectively, progressing toward delivering on our mission to bring new practical, treatment options to peanut allergic children and their families. Read the full earnings here: https://bit.ly/4lQC40u